Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
- Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™
- Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies
AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
